MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance
Drug Resistance Updates · 2025-07 · 81 · 101246
DOI: 10.1016/j.drup.2025.101246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-07. Verfasst von Jiawen Xu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing University Medical School, Nanjing, China. Hauptthemen laut MEDLINE: Ferroptosis, Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Natural Science Foundation of Anhui Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
RNA-binding proteins (RBPs) are critical regulators in tumorigenesis and therapy resistance by modulating RNA metabolism. However, the role of RBPs in hepatocarcinogenesis and progression remains elusive. Here, RBPs screening and integrating analyses identify major vault protein (MVP) as an oncogenic RBP in the occurrence of hepatocellular carcinoma (HCC) and sorafenib resistance via suppressing ferroptosis. Mechanistically, reactive oxygen species (ROS) induces STAT3-mediated MVP transcription activation and high expression in HCC cells. Subsequently, phosphoglycerate mutase family member 5 (PGAM5) directly dephosphorylates MVP at S873, facilitating its binding to the mRNA of iron-sequestering cytokine LCN2 and maintains its stability, thereby attenuating ferroptosis by reducing lipid peroxidation and intracellular Fe2+ content following sorafenib treatment. Notably, tenapanor, a potent pharmacological inhibitor of MVP, effectively disrupts the interaction between MVP and LCN2 mRNA and enhances ferroptosis and sorafenib sensitivity. Collectively, these findings underscore the central role of MVP in hepatocarcinogenesis and offer promising avenues to improve HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing University Medical School, Nanjing, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University; MOE Innovation Center for Basic Research in Tumor Immunotherapy; Anhui Province Key Laboratory of Tumor Immune Microenviron…
- Crown Bioscience Inc, Suzhou, China.
- Medical College, Yangzhou University, Yangzhou, China.
- School of Medicine, University of Missouri, Columbia, USA.
- Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.
Förderung
- Natural Science Foundation of Anhui Province
- National Natural Science Foundation of China
Zitieren
APA
Xu, J., Wang, B., Liu, Q., Guo, S., Chen, C., Wu, J., Zhao, X., Li, M., Ma, Z., Zhou, S., Qian, Y., Huang, Y., Wang, Z., Shu, C., Xu, Q., Ben, J., Wang, Q., & Wang, S. (2025). MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance. Drug Resistance Updates, 81, 101246. https://doi.org/10.1016/j.drup.2025.101246
Vancouver
Xu J, Wang B, Liu Q, Guo S, Chen C, Wu J, et al. MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance. Drug Resistance Updates. 2025;81:101246. doi:10.1016/j.drup.2025.101246
BibTeX
@article{Xu2025,
author = {Xu, Jiawen and Wang, Bo and Liu, Qiaoyu and Guo, Sheng and Chen, Chen and Wu, Jun and Zhao, Xiaoya and Li, Mengmeng and Ma, Zhuang and Zhou, Shimeng and Qian, Yun and Huang, Yijin and Wang, Zhangding and Shu, Chuanjun and Xu, Qingxiang and Ben, Jingjing and Wang, Qiang and Wang, Shouyu},
title = {MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance},
journal = {Drug Resistance Updates},
year = {2025},
volume = {81},
pages = {101246},
doi = {10.1016/j.drup.2025.101246}
}
EUVIMED